2023 World Conference on Lung Cancer (Posters)-EP07.02. MIDRIXNEO-LUNG: Safety and Immunogenicity of a Neoantigen-Presenting Autologous Dendritic Cell Therapy in Resected NSCLC Patients

EP07.02. MIDRIXNEO-LUNG: Safety and Immunogenicity of a Neoantigen-Presenting Autologous Dendritic Cell Therapy in Resected NSCLC Patients - PDF(Abstract)

Back to course

Pdf Summary

A study presented at the WCLC 2023 conference reported on the safety and immunogenicity of a novel dendritic cell therapy in patients with resected non-small cell lung cancer (NSCLC). The study aimed to explore the potential of adjuvant immunotherapy in controlling residual disease and reducing relapse rates.<br /><br />The researchers used a personalized approach, identifying tumor neoantigens from each patient's tumor samples. These neoantigens were then encoded into mRNA and loaded onto dendritic cells. The dendritic cells were then administered to the patients intravenously every two weeks.<br /><br />The study included 10 patients, and dendritic cell batches were successfully manufactured for 6 of them. The doses administered were well-tolerated with only mild toxicity observed. Systemic immune responses specific to the neoepitopes were detected in 5 out of 6 evaluable patients. These responses included expansion of existing T-cell responses as well as de novo responses in both CD8 and CD4 compartments. The T-cell responses demonstrated high specificity for the mutation-containing sequences.<br /><br />Importantly, the study found that even the lowest dose of dendritic cells was able to trigger de novo neoepitope-specific T-cell responses, and these responses persisted for up to 19 months after the last dose. However, two of the treated patients experienced metastatic relapse, with one showing no T-cell responses after the therapy.<br /><br />Overall, the study demonstrated the feasibility and safety of the dendritic cell therapy in resected NSCLC patients. The personalized approach of using tumor neoantigens showed promising results in eliciting specific and long-lasting T-cell responses. The researchers suggest that further optimization of the manufacturing pipeline and implementation in advanced disease stages could expand the use of this therapy.

Asset Subtitle

Karim Vermaelen

Meta Tag

Speaker Karim Vermaelen

Topic Early-Stage NSCLC: New Technology & Innovations

Keywords

WCLC 2023 conference

dendritic cell therapy

non-small cell lung cancer

safety

immunogenicity

adjuvant immunotherapy

tumor neoantigens

intravenous administration

immune responses

long-lasting responses